Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SPCD-4-79
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Supercede Therapeutics Provides Update on Novel Oral Treatment for Obesity
Details : Supercede's lead drug, SPCD-4-79, is an orally bioavailable, low molecular weight compound that blocks the signaling activity of both isoforms of the Activin receptor Type II, ACTRIIA and ACTRIIB.
Product Name : SPCD-4-79
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 24, 2025
Lead Product(s) : SPCD-4-79
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable